- Solid company
- Has had downward trend for weeks but is now at support
- For the six months ended 30 June 2021, Amgen, Inc. revenues increased less than 1% to $12.43B.
- Net income decreased 42% to $2.11B. Revenues reflect Prolia segment increase of 20% to $1.57B
- Other revenues segment increase of 28% to $721M, also reflect Enbrel segment decrease of14% to $2.07B, Neulasta segment decrease of 19% to $968M.
- Net income was partially offset by Research and development increase of 7% to $2.05B (expense), Selling.
- Has had downward trend for weeks but is now at support
- For the six months ended 30 June 2021, Amgen, Inc. revenues increased less than 1% to $12.43B.
- Net income decreased 42% to $2.11B. Revenues reflect Prolia segment increase of 20% to $1.57B
- Other revenues segment increase of 28% to $721M, also reflect Enbrel segment decrease of14% to $2.07B, Neulasta segment decrease of 19% to $968M.
- Net income was partially offset by Research and development increase of 7% to $2.05B (expense), Selling.